• United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options, acquiring 9,500 common shares at USD 146.03 on May 22, 2026.
• Rothblatt sold 9,500 common shares the same day in multiple trades, with prices ranging about USD 563.27 to USD 569.73.
• Directly held common shares ended at 40,513 following the transactions.
• Directly held stock options ended at 173,910 following the exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000060), on May 26, 2026, and is solely responsible for the information contained therein.